RxDoctor Payments Data

Amanda Thompson

Nurse Practitioner · Idaho Falls, IDNPI 1144690413

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $52,935 of the $66,691 with a category attached, or 79.4%. AbbVie accounts for 90.7% of it on its own, with 39 other manufacturers making up the rest. Among nurse practitioner clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$66,691in general payments, 2019–2025

Across 545 payments — averaging $122.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$61K
  • Teva Pharmaceuticals USA, Inc.$894
  • Biogen$577
  • EMD Serono, Inc.$383
  • AstraZeneca$341
  • TG Therapeutics, Inc.$332
  • plus $4K from 34 others

What the payments were for

  • Speaking & faculty fees$52,93579%
  • Travel & lodging$4,1306%
  • Food & beverage$9,07214%
  • Education$5531%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$66,691 in reported general payments places this provider in the 95th percentile of 570 nurse practitioner providers in Idaho.

See all nurse practitioner providers in Idaho

Medicare billing

Part B allowed, 2024
$41,353
Medicare patients
217
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XywavSodium,calcium,mag,pot Oxybate12$171,446
QuliptaAtogepant51$55,689
UbrelvyUbrogepant30$37,414
Aimovig AutoinjectorErenumab-Aooe46$36,963
Emgality PenGalcanezumab-Gnlm34$25,091
Ajovy AutoinjectorFremanezumab-Vfrm23$15,883
Modafinil22$12,206
XcopriCenobamate11$10,443
Zonisamide90$6,767
Tiagabine Hcl13$5,426
BelsomraSuvorexant11$4,589
Levetiracetam65$2,603
Lacosamide21$2,523
Oxcarbazepine22$2,512
Carbidopa-LevodopaCarbidopa/Levodopa92$2,255

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Ubrelvy$60,503$93,10381 claims
SK Life Science, Inc.Xcopri$184$10,44311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 570 nurse practitioner providers in Idaho.

Other nurse practitioner in Idaho Falls

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →